Contact Us

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Ischemic injury occurs due to the insufficient blood supply to the tissue. According to the National Institutes of Health, the burden of cardiovascular diseases (CVDs) such as stroke and myocardial infarction is increasing rapidly at a global level. This would, in turn, increase the number of patients with ischemia-reperfusion injury. The condition lowers the level of ATP production and thus inactivates ion-exchange channels. Ischemia reperfusion injury is a critical medical condition that poses a major therapeutic challenge for physicians. Key players in the market are involved in research and development of novel drugs and treatment which is expected to escalate the growth of the global ischemia reperfusion injury therapeutics market.

The rising number of tissue damage cases and the increasing awareness about ischemia reperfusion injury is expected to drive growth of the global ischemia reperfusion injury therapeutics market during the forecast period. Moreover, the increasing investments by key players in research & development of novel treatment for ischemia reperfusion are estimated to boost the market growth. For instance, in November 2018, Revive Therapeutics received the Orphan Drug designation for Cannabidiol from the U.S. Food and Drug Administration (FDA) to prevent ischemia reperfusion injury resulting from organ transplantation.

Global Ischemia Reperfusion Injury Therapeutics Market - Impact of Coronavirus (Covid-19) Pandemic

The global ischemia reperfusion therapeutics market growth has been affected by the COVID-19 pandemic as it has become difficult to conduct research in the current situation. Thus, several market players are focusing on strategies which can help patients with ischemic reperfusion injury to remain agile during the disruption of healthcare services. Moreover, several government organizations across the globe are implementing policies and regulations to deal with the current crisis.

The all-inclusive version of the report will include the impact of COVID-19 and the probable changes in the future outlook of the industry, by taking into account the technological, social, political, and economical parameters.

The ischemia reperfusion injury therapeutics market is estimated to be valued at US$ 1,582.33 million in 2020 and is expected to rise at a CAGR of 5.4% during the forecast period (2020-2027).

Figure 1: Global Ischemia Reperfusion Injury Therapeutics Market Share (%) Analysis, By Distribution Channel, 2020

Ischemia Reperfusion Injury Therapeutics  | Coherent Market Insights

An increase in the number of mergers & acquisitions, product launches, and approvals from drug regulatory authorities are expected to propel the growth of the global ischemia reperfusion injury therapeutics market.

Key players in the market are involved in mergers & acquisitions to develop and launch advanced drugs and treatment in the market. The drug launches and approvals from drug regulatory authorities are expected to facilitate the market growth and create lucrative growth opportunities for players operating in the market during the forecast period.

For instance, in November 2019, Faraday Pharmaceuticals announced positive results from phase II clinical trials of FDY-5301 for ischemia reperfusion injury treatment following a STEMI heart attack. FDY-5301 is a formulated, patented, elemental reducing agent that contains sodium iodide. It destroys the hydrogen peroxide that is naturally generated as a response to acute ischemia reperfusion injury and also contributes to loss of muscle function and mass.

In January 2020, Revive Therapeutics Ltd., a cannabis life sciences company, provided an update regarding its clinical development plan for treatment of liver disorders. The aim of the company is to expand its product pipeline by leveraging its FDA orphan drug designation for Cannabidiol in the prevention of ischemia reperfusion injury from organ transplantation.

request-sample

Ischemia Reperfusion Injury Therapeutics Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2019: US$ 1,582.33 Mn
Historical Data for: 2017 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 5.4% 2027 Value Projection: US$ 2,290.1 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Indication: Heart Injury, Kidney Injury, Intestine Injury, Other Injury.
  • By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, Others.
Companies covered:

Omeros Corporation, Nyken B.V., Opsona Therapeutics Limited, Pharming Group N.V., Orexo AB, PledPharma AB, Proteo, Inc., Prolong Pharmaceuticals, Prothix BV, Zealand Pharma A/S, Stealth BioTherapeutics Inc., Amyndas Pharmaceuticals LLC, Antipodean Pharmaceuticals, Inc., Angion Biomedica Corp., Bayer AG, Bolder Biotechnology, Inc., Biomedica Management Corporation, Curatis Pharma GmbH, Erimos Pharmaceuticals, LLC, Ensemble Therapeutics Corporation, and Gilead Sciences, Inc.

Growth Drivers:
  • The increasing investment in research and development of novel treatments for ischemia reperfusion injury
  • The growing awareness about treatment for ischemia reperfusion injury
Restraints & Challenges:
  • High cost associated with the treatment
  • Risks involved in ischemia reperfusion injury treatment

Global Ischemia Reperfusion Injury Therapeutics Market – Regional Analysis

The market in North America accounted for majority of the share in the global ischemia reperfusion therapeutics market in 2019 owing to the increasing focus of key players on research & development and obtaining FDA approvals. For instance, in May 2019, Abiomed received the U.S. FDA approval for its STEM DTU trial of delayed ischemic reperfusion injury with impella CP. The trial will test the hypothesis that unloading the left ventricle for 30 minutes before ischemia reperfusion injury will reduce myocardial damage from a heart attack and lead to a reduction in future heart failure-related events.

Furthermore, Asia Pacific is expected to witness significant CAGR during the forecast period owing to research and development and collaborative agreements among key industry players. For instance, in May 2016, NeuroVive Asia and Sanofi entered a collaboration agreement to develop and commercialize CicloMulsion in South Korea for treatment of ischemia reperfusion injury in cardiovascular disease (CVDs). Under this agreement, NeuroVive Asia received upfront payment and royalty on future sales in the country.

Figure 2: Global Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2027

Ischemia Reperfusion Injury Therapeutics  | Coherent Market Insights

Global Ischemia Reperfusion Injury Therapeutics Market - Competitive Landscape

Key players operating in the global ischemia reperfusion injury therapeutics market are Omeros Corporation, Nyken B.V., Opsona Therapeutics Limited, Pharming Group N.V., Orexo AB, PledPharma AB, Proteo, Inc., Prolong Pharmaceuticals, Prothix BV, Zealand Pharma A/S, Stealth BioTherapeutics Inc., Amyndas Pharmaceuticals LLC, Antipodean Pharmaceuticals, Inc., Angion Biomedica Corp., Bayer AG, Bolder Biotechnology, Inc., Biomedica Management Corporation, Curatis Pharma GmbH, Erimos Pharmaceuticals, LLC, Ensemble Therapeutics Corporation, and Gilead Sciences, Inc.

Ischemia reperfusion injury (IRI), also known as reoxygenation injury, is tissue damage that arises when blood supply returns to the tissue (reperfusion) after a period of lack of oxygen (ischemia). The symptoms of ischemia injury include bradycardia, headache, hypertension, and seizures.

Market Dynamics

The increase in the number of tissue damage cases and the growing awareness about treatment of reperfusion injury are major factors boosting growth of the global ischemia reperfusion therapeutics market. Moreover, introduction of novel drugs for treatment of complications related to ischemia reperfusion, and the rising research & development activities are propelling the market growth. For instance, in November 2019, Faraday Pharmaceuticals announced positive top-line results from the phase II trial of FDY-5301 for ischemia reperfusion injury therapeutics treatment.

Moreover, factors such as the rising incidence of ischemic reperfusion injury across the globe, and strategic acquisitions of key players for developing novel treatment are expected to favor growth of the market during the period of forecast.

Key features of the study:

  • This report provides in-depth analysis of the global ischemia reperfusion injury therapeutics market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2020-2027, considering 2019 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • The study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the global ischemia reperfusion injury therapeutics market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, key developments, and strategies
  • Key players covered as a part of this study are Omeros Corporation, Nyken B.V., Opsona Therapeutics Limited, Pharming Group N.V., Orexo AB, PledPharma AB, Proteo, Inc., Prolong Pharmaceuticals, Prothix BV, Zealand Pharma A/S, Stealth BioTherapeutics Inc., Amyndas Pharmaceuticals LLC, Antipodean Pharmaceuticals, Inc., Angion Biomedica Corp., Bayer AG, Bolder Biotechnology, Inc., Biomedica Management Corporation, Curatis Pharma GmbH, Erimos Pharmaceuticals, LLC, Ensemble Therapeutics Corporation, and Gilead Sciences, Inc.
  • Insights from this report would allow marketers and management authorities of companies to make an informed decision with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global ischemia reperfusion injury therapeutics market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers in the global ischemia reperfusion therapeutics market, research and consulting firms, new entrants, and financial analysts.

Detailed Segmentation:

  • Global Ischemia Reperfusion Injury Therapeutics Market, By Indication:
    • Heart Injury
    • Kidney Injury
    • Intestine Injury
    • Other Injury
  • Global Ischemia Reperfusion Injury Therapeutics Market, By Distribution Channel:
    • Retail Pharmacies
    • Hospital Pharmacies
    • Others
  • Global Ischemia Reperfusion Injury Therapeutics Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
      • By Indication:
        • Heart Injury
        • Kidney Injury
        • Intestine Injury
        • Other Injury
      • By Distribution Channel:
        • Retail Pharmacies
        • Hospital Pharmacies
        • Others
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
      • By Indication:
        • Heart Injury
        • Kidney Injury
        • Intestine Injury
        • Other Injury
      • By Distribution Channel:
        • Retail Pharmacies
        • Hospital Pharmacies
        • Others
    • Asia Pacific
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
      • By Indication:
        • Heart Injury
        • Kidney Injury
        • Intestine Injury
        • Other Injury
      • By Distribution Channel:
        • Retail Pharmacies
        • Hospital Pharmacies
        • Others
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
      • By Indication:
        • Heart Injury
        • Kidney Injury
        • Intestine Injury
        • Other Injury
      • By Distribution Channel:
        • Retail Pharmacies
        • Hospital Pharmacies
        • Others
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
      • By Indication:
        • Heart Injury
        • Kidney Injury
        • Intestine Injury
        • Other Injury
      • By Distribution Channel:
        • Retail Pharmacies
        • Hospital Pharmacies
        • Others
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
      • By Indication:
        • Heart Injury
        • Kidney Injury
        • Intestine Injury
        • Other Injury
      • By Distribution Channel:
        • Retail Pharmacies
        • Hospital Pharmacies
        • Others
  • Company Profiles
    • Omeros Corporation
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Nyken B.V.
    • Opsona Therapeutics Limited
    • Pharming Group N.V.
    • Orexo AB
    • PledPharma AB
    • Proteo, Inc.
    • Prolong Pharmaceuticals
    • Prothix BV
    • Zealand Pharma A/S
    • Stealth BioTherapeutics Inc.
    • Amyndas Pharmaceuticals LLC
    • Antipodean Pharmaceuticals, Inc.
    • Angion Biomedica Corp.
    • Bayer AG
    • Bolder Biotechnology, Inc.
    • Biomedica Management Corporation
    • Curatis Pharma GmbH
    • Erimos Pharmaceuticals, LLC
    • Ensemble Therapeutics Corporation
    • Gilead Sciences, Inc.

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Indication
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Pipeline Analysis
    • Key Developments
    • Acquisition, Collaborations & Partnerships
    • Epidemiology
  4. Global Ischemia Reperfusion Injury Therapeutics Market, Impact of Coronavirus (COVID-19) Pandemic
    • During-COVID situation
    • Post-COVID demand
  5. Global Ischemia Reperfusion Injury Therapeutics Market, By Indication, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Heart Injury
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Kidney Injury
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Intestine Injury
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Other Injury
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  6. Global Ischemia Reperfusion Injury Therapeutics Market, By Distribution Channel, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  7. Global Ischemia Reperfusion Injury Therapeutics Market, By Region, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2020 and 2027(%)
      • Y-o-Y Growth Analysis, By Region, 2017 –2027
      • Regional Trends
    • North America
      • Market Size and Forecast, By Types, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Types, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Types, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • China
        • Japan
        • India
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast, By Types, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Africa
      • Market Size and Forecast, By Types, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Million)
        • North Africa
        • Central Africa
        • South Africa
    • Middle East
      • Market Size and Forecast, By Types, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • GCC
        • Israel
        • Rest of Middle East
  8. Competitive Landscape
    • Company Profiles
      • Nyken B.V.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Omeros Corporation
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Opsona Therapeutics Limited
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Orexo AB
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Pharming Group N.V.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • PledPharma AB
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Prolong Pharmaceuticals
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Proteo, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Prothix BV
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Stealth BioTherapeutics Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Zealand Pharma A/S
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Amyndas Pharmaceuticals LLC
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Angion Biomedica Corp.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Antipodean Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Bayer AG
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Biomedica Management Corporation
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Bolder Biotechnology, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Curatis Pharma GmbH
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Ensemble Therapeutics Corporation
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Erimos Pharmaceuticals, LLC
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Gilead Sciences, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
  9. Section
    • References
    • Research Methodology
    • About Us and Sales Contact

*Browse 26 market data tables and 28 figures on "Global Ischemia Reperfusion Injury Therapeutics Market” - Forecast to 2027”

Frequently Asked Questions

The global ischemia reperfusion injury therapeutics market is expected to register a CAGR of 5.42% during the forecast period (2020-2027).
The value of the global market for the ischemia reperfusion injury therapeutics is estimated to be valued at US$ 1,582.3 million in 2020.
The prominent players in global ischemia reperfusion injury therapeutics market are Omeros Corporation, Nyken B.V., Opsona Therapeutics Limited, Pharming Group N.V., Orexo AB, PledPharma AB, Proteo, Inc., Prolong Pharmaceuticals, Prothix BV, Zealand Pharma A/S, Stealth BioTherapeutics Inc., Amyndas Pharmaceuticals LLC, Antipodean Pharmaceuticals, Inc., Angion Biomedica Corp., Bayer AG, Bolder Biotechnology, Inc., Biomedica Management Corporation, Curatis Pharma GmbH, Erimos Pharmaceuticals, LLC, Ensemble Therapeutics Corporation, and Gilead Sciences, Inc.
The ischemia reperfusion injury therapeutics market is expected to be valued at US$ 2,290.1 million in 2027.
The major region in the ischemia reperfusion injury therapeutics market is North America.
Increasing investments in research and development of a novel treatment for ischemia and reperfusion injury, and the rising number of tissue damage cases.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner